Familial history of cancer and leukemia in children younger than 2 years of age in Brazil

被引:5
|
作者
Couto, Arnaldo C. [1 ]
Ferreira, Jeniffer D. [1 ]
Koifman, Sergio [1 ]
Pombo-de-Oliveira, Maria S. [2 ]
机构
[1] Minist Hlth, Oswaldo Cruz Fdn FIOCRUZ, Natl Sch Publ Hlth, BR-21041210 Rio De Janeiro, RJ, Brazil
[2] Natl Canc Inst, Res Ctr, Pediat Hematol Oncol Program, Rio De Janeiro, RJ, Brazil
关键词
acute lymphoblastic leukemia; case-control study; childhood leukemia; familial history of cancer; ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAST-CANCER; RISK; GENETICS;
D O I
10.1097/CEJ.0b013e3283581d1f
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to determine the contribution of a familial history of cancer (FHC) to the development of leukemia in children below 2 years of age. This is a national hospital-based case-control study of children 0-24 months of age recruited from 15 Brazilian hospitals from several regions providing oncological care and local general hospitals. Participants' FHC antecedents were obtained through face-to-face interviews with the mothers of cases and controls using a standardized questionnaire. Unconditional logistic regression was used to determine crude and adjusted (adj.) odds ratios (OR), and the respective 95% confidence intervals (CI), of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) after adjustment for selected variables. FHC antecedents were obtained from 178 ALL, 51 AML, and 428 controls. FHC in second-degree relatives (grandparents, uncles, cousins) showed an adj. OR = 1.66 (95% CI 1.12-2.45) for ALL. Antecedents of two or more relatives with cancer showed a statistically significant two-fold higher risk of either ALL or AML. Paternal, and joint paternal and maternal antecedents of cancer also showed statistically significant higher adj. OR, respectively: 1.80 and 1.89 for ALL, and 2.34 and 3.23 for AML. Hematological malignancies among second-degree relatives showed an adj. OR = 3.48 (95% CI 1.72-7.09) for ALL. According to the anatomic site, antecedents of leukemia/lymphoma among case relatives, compared with the control ones, showed an OR = 2.98 (95% CI 1.52-5.82) for ALL, whereas stomach cancer antecedents showed an OR = 3.55 (95% CI 1.02-12.39) for AML. The observed results support the hypothesis that FHC antecedents are associated with leukemogenesis in children below 2 years of age. European Journal of Cancer Prevention 22:151-157 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:151 / 157
页数:7
相关论文
共 50 条
  • [1] Smoking in households in Brazil with children younger than 5 years of age
    Gonçalves-Silva, RMV
    Valente, JG
    Lemos-Santos, MGF
    Sichieri, R
    [J]. REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2005, 17 (03): : 163 - 169
  • [2] BRAIN-TUMORS IN CHILDREN YOUNGER THAN 2 YEARS OF AGE
    DUFFNER, PK
    COHEN, ME
    MYERS, MH
    BLUMENSON, L
    KOLONEL, L
    SWANSON, GM
    LATOURETTE, H
    FLANNERY, J
    CHILD, MA
    THOMPSON, DJ
    DAVIS, C
    BURROWS, RW
    [J]. ANNALS OF NEUROLOGY, 1983, 14 (03) : 375 - 375
  • [3] Endoscopic third ventriculostomy in children younger than 2 years of age
    Baldauf, Joerg
    Oertel, J.
    Gaab, Michael R.
    Schroeder, Henry W. S.
    [J]. CHILDS NERVOUS SYSTEM, 2007, 23 (06) : 623 - 626
  • [4] Efficacy and tolerability of topiramate in children younger than 2 years of age
    Fons, MC
    Valencia, I
    Kothare, SV
    Khurana, DS
    Yum, S
    Hardison, HH
    Legido, A
    [J]. NEUROLOGY, 2004, 62 (07) : A70 - A70
  • [5] Endoscopic third ventriculostomy in children younger than 2 years of age
    Jörg Baldauf
    J. Oertel
    Michael R. Gaab
    Henry W. S. Schroeder
    [J]. Child's Nervous System, 2007, 23 : 623 - 626
  • [6] Efficacy and tolerability of topiramate in children younger than 2 years of age
    Fons, FC
    Valencia, I
    Kothare, SV
    Khurana, DS
    Yum, SS
    Hardison, HH
    Legido, A
    [J]. ANNALS OF NEUROLOGY, 2004, 56 : S116 - S116
  • [7] Complications of adenotonsillectomy in children with OSAS younger than 2 years of age
    Slovik, Y
    Tal, A
    Shapira, Y
    Tarasiuk, A
    Leiberman, A
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2003, 67 (08) : 847 - 851
  • [8] Efficacy of levetiracetam in children with epilepsy younger than 2 years of age
    Krief, Patricia
    Kan, Li
    Maytal, Joseph
    [J]. JOURNAL OF CHILD NEUROLOGY, 2008, 23 (05) : 582 - 584
  • [9] Safety of gadoterate meglumine in children younger than 2 years of age
    Farmakis, Shannon G.
    Hardy, Anna K.
    Mahmoud, Shamsheldeen Y.
    Wilson-Flewelling, Scott A.
    Tao, Ting Y.
    [J]. PEDIATRIC RADIOLOGY, 2020, 50 (06) : 855 - 862
  • [10] Safety of gadoterate meglumine in children younger than 2 years of age
    Shannon G. Farmakis
    Anna K. Hardy
    Shamsheldeen Y. Mahmoud
    Scott A. Wilson-Flewelling
    Ting Y. Tao
    [J]. Pediatric Radiology, 2020, 50 : 855 - 862